Members
- Christoph Höller (Leader)
- Celeste Lebbé (Leader)
- Claus Garbe
- Axel Hauschild
- Ulrike Leiter-Stöppke
- Caroline Robert
- Philippe Saiag
Scope and objectives
The European Task Force Investigator Initiated Trials (IITs) in dermato-oncology refers to clinical studies initiated by investigators rather than pharmaceutical companies, focused on the diagnosis, treatment, and management of skin cancers, particularly melanoma and non-melanoma skin cancers. These trials aim to evaluate new therapeutic strategies, investigate treatment efficacy, and improve patient outcomes in dermato-oncology.
The group’s primary objectives are:
- Investigator-Driven: The trials are initiated and conducted by clinical investigators, often in collaboration with academic institutions and healthcare centers.
- Focus on Innovation: IITs allow for the exploration of novel treatment modalities, including combination therapies, new drug applications, and personalized medicine approaches tailored to individual patient profiles.
- Collaboration: These trials can involve multidisciplinary teams, including dermatologists, medical oncologists, pathologists, researchers and industry partners promoting a collaborative approach to skin cancer treatment.
- Ethical Considerations: IITs are designed to uphold high ethical standards, ensuring informed consent, patient safety, and adherence to regulatory guidelines.
- Contribution to Knowledge: Results from these trials contribute valuable data to the broader scientific community, enhancing the understanding of dermato-oncology and informing future research directions.
Overall, European Task Force IITs serve as a crucial mechanism for advancing research and improving clinical practices in the management of skin cancers, fostering innovation and collaboration among researchers and clinicians throughout Europe.